10 Best Newsletters to Prevent Brain Rot in 2025

Absci's AI-generated drug ABS-201 targets the telogen (shedding) phase directly, bypassing initial hair loss from minoxidil. It reactivates follicles and repigments hair, with preclinical data showing reversal in balding models. Phase 1 human trials launched mid-2025; could hit market by 2028.

Eirion Therapeutics' ET-02 flips a metabolic pathway in follicle cells, outperforming existing drugs in Phase 1 (N=24) with 2x hair density gains. Prevents greying too; Phase 2 (N=150) starts Q1 2026. Targets 80M US sufferers, with potential for prevention.

UC Irvine's injectable AMP-303 sends a 'print signal' to dormant follicles, yielding 15%+ increase in thick hair after one treatment (vs. placebo). Effects last 150+ days; addresses recent and long-term loss. Phase 2 trials ongoing, with human data from 2025 study.

Madrid's San Carlos Hospital combined fat-derived stem cells with ATP (energy molecule) to reverse pattern baldness in mice males regrew fur, 90% females fully revived. Human trials planned for 2026; focuses on follicle energy dysfunction.

UVA discovered latent stem cells persist in bald scalps; depleting them halts growth, but reactivating could repopulate follicles. Lab tests on human samples show migration potential for regrowth; early-stage, but paradigm-shifting for scarring alopecia.

MIT's microneedle patch delivers drugs to restore immune privilege in follicles, reversing alopecia areata in mice (full regrowth). Human trials via Phase 1 in 2025; targets autoimmune-driven loss, not just pattern baldness.